Skip to content

Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation

Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00833014
Acronym
DYANA
Enrollment
130
Registered
2009-01-30
Start date
2008-12-31
Completion date
2010-12-31
Last updated
2009-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mitral Valve Regurgitation

Brief summary

The device is a dynamic annuloplasty ring/band that is able to be adjusted in order to correct for mitral regurgitation intraoperatively or postoperatively, off-pump.

Interventions

DEVICEDynamic Annuloplasty Ring (with option to adjust off-pump)

Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.

Sponsors

MiCardia Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. This patient requires mitral valve repair with or without concomitant procedures such as coronary artery bypass or another valve reconstruction or replacement. 2. This patient has been diagnosed with a diseased natural valve, based on echocardiography and is a candidate for mitral valve repair. 3. This patient is in satisfactory condition, based on the physical exam and investigator's experience, to be an average or better operative risk. (i.e., likely to survive one year postoperatively). 4. This patient is geographically stable and willing to return to the implant center for follow-up visits. 5. This patient has been adequately informed of his/her participation in the clinical study, and of what will be required of him/her, in order to comply with the protocol.

Exclusion criteria

1. This patient is less than eighteen (18) years of age. 2. This patient has a non-cardiac major or progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient, or results in a life expectancy of less than twelve months. 3. This patient has an ejection fraction \< 30%. 4. This patient has a heavily calcified annulus or leaflets. 5. This patient presents with active endocarditis or has had active endocarditis in the last 3 months. 6. This patient is pregnant (urine HCG test result positive) or lactating. 7. This patient is an intravenous drug abuser or alcohol abuser. 8. This patient has a previously implanted prosthetic mitral valve. 9. This patient requires mitral valve replacement. 10. This patient has a creatinine level \> 2.0 mg/dl 11. This patient has had congestive heart failure within the past 6 months requiring surgical treatment. 12. This patient has had a coronary artery ischemic event within the past 6 months. 13. This patient has a known life threatening, non-cardiac disease that will limit the patient's life expectancy to less than one year. 14. This patient is unable to take Coumadin. 15. This patient has a known untreatable allergy to contrast media or nickel. 16. This patient has had a cerebral vascular event within the past 6 months. 17. This patient is a prisoner (U.S.A. Only). 18. This patient is participating in concomitant research studies of investigational products. 19. This patient will not agree to return to the implant center for the required number of follow-up visits or is geographically unavailable for follow-up.

Design outcomes

Primary

MeasureTime frame
Freedom from major complications and SAM (Systolic Anterior Motion)6 months

Secondary

MeasureTime frame
Ability to adjust annuloplasty ring off-pump post implantation to correct for residual regurgitation, reduction of mitral valve regurgitation at follow-up visits (discharge, 30 days, 6 months)6 months

Countries

Canada, Germany, Netherlands

Contacts

Primary ContactJody L Errandi, M.S.
jerrandi@micardia.com949.951.4888

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026